Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 2170

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 1A
Chunk 2170
---
;

    ●
    the
    cost of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory
    approval in regions where we choose to commercialize our products on our own; 

    ●
    the
    timing and amounts of any milestone or royalty payments we may be required to make or may be entitled to receive under license agreements;

    ●
    the
    costs of building out our infrastructure including hiring additional clinical, quality control and manufacturing personnel;

    ●
    the
    costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for
    any of our product candidates for which we receive marketing approval;

    ●
    the
    revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval;

    ●
    the
    costs of operating as a public company; and

    ●
    the
    extent to which we acquire or in-license other product candidates and technologies.

We
cannot be certain that additional funding will be available on acceptable terms, or at all. Until we can generate sufficient revenue
to finance our cash requirements, which we may never do, we expect to finance our future cash needs through a combination of public or
private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing or distribution
arrangements. This additional funding may not be sufficient for us to fund any of our products through regulatory approval.

72

To
the extent that we raise additional capital through the sale of common stock or securities convertible or exchangeable into common stock,
your ownership interest will be diluted. In addition, any debt financing may subject us to fixed payment obligations and covenants limiting
or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.
If we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing
arrangements with third parties, we may have to relinquish certain valuable intellectual property or other rights to our product candidates,
technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to us. We also may be
required to seek collaborators for any of our product candidates at an earlier stage than otherwise would be desirable or relinquish
our rights to product candidates or technologies that we otherwise would seek to develop or commercialize ourselves. Market volatility
and unforeseen events, such as the conflict between Russia and Ukraine, could also